Cytokinetics Inc
Q1 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: +0.73%.
Did CYTK Beat Earnings? Q1 2026 Results
Cytokinetics delivered a sharply mixed first quarter for fiscal 2026, with a dramatic revenue beat offset by a slight earnings miss as the company's newly launched heart drug MYQORZO began generating commercial traction. Revenue surged to $19.36 million, a 1,125.8% increase from $1.58 million a year ago, well ahead of the $9.08 million consensus estimate, driven by $4.79 million in early MYQORZO product sales across roughly nine weeks on the market, a $11.93 million license milestone triggered by that first U.S. sale under the Bayer agreement, and $2.64 million in collaboration revenues. However, the company posted a loss per share of $1.67, just shy of the $1.63 consensus estimate, as SG&A expenses nearly doubled to $104.90 million from $57.37 million to support the commercial launch. Looking ahead, the company maintained its full-year combined R&D and SG&A expense guidance of $830 million to $870 million, while analysts have meaningfully lifted their 2026 revenue forecasts following positive Phase 3 data in non-obstructive HCM and a $700 million equity raise that extended the company's financial runway.
- Strong initial U.S. launch of MYQORZO with over 275 prescribing HCPs and approximately 680 patients in first partial quarter
- $11.9 million milestone payment from Bayer tied to first U.S. sale of MYQORZO
- Over 70% of patients on paid prescriptions indicating favorable payer coverage
- Over 1,400 HCPs REMS certified as of March 31, 2026
“The U.S. launch of MYQORZO commenced strongly in late January and continues to accelerate. We promptly activated a solid prescriber base of early adopters and are encouraged by initial commercial metrics that are exceeding our expectations.”
Cytokinetics CEO, on the earnings call
Forward Guidance & Outlook
Cytokinetics maintained its full-year 2026 financial guidance for GAAP combined R&D and SG&A expenses of $830 million to $870 million, including $120 million to $130 million in non-cash stock-based compensation. This guidance excludes collaboration expenses, potential costs related to commercialization of aficamten in non-obstructive HCM, and GAAP adjustments from subsequent events including business development activities. The company expects to launch MYQORZO in Germany in Q2 2026, complete adolescent cohort enrollment in CEDAR-HCM in Q4 2026, and has a PDUFA date of November 14, 2026 for the MAPLE-HCM supplemental NDA. Patient enrollment in COMET-HF (omecamtiv mecarbil) is expected to continue through 2026, and AMBER-HFpEF Cohort 1 enrollment (ulacamten) is expected to complete in H2 2026.
CYTK YoY Financials
CYTK Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.